Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial

作者：Gail Matthews, Simone Jacoby, Margaret Borok, Nnakelu Eriobu, Richard Kaplan, Nagalingeswaran Kumarasamy, Jaclyn Bennet, Anchalee Avihingsanon, Ploenchan Chetchotisakd, Sandra Wagner Cardoso, Iskandar Azwa, Marcelo Losso, Dannae Brown, Dona Arlinda, Jolie Hutchinson, Anthony D. Kelleher, Mohamed Cissé, Sounkalo Dao, Mark N. Polizzotto, Sean Emery, Matthew Law, Emmanuelle Papot, Muhammad Karyana, Sergio Lupo, A.M. Solari, Beatriz Grinsztejn, Marcello Wolff, Jaime Andrade‐Villanueva, Juan Luis Mosqueda Gómez, Ting Soo Chow, Lerato Mohapi, Evy Yunihastuti, Usman Hadi, Sudirman Katu, Yanri Wijayanti Subronto, H. Clifford Lane, Leonardo Perelis · 发表于：The Lancet HIV · 年份：2024 · DOI：10.1016/s2352-3018(24)00089-4 · 被引用次数：31 · 研究领域：HIV/AIDS drug development and treatment、HIV/AIDS Research and Interventions、HIV-related health complications and treatments